BOSTON, Sept. 29, 2025 /PRNewswire/ — Embleema, in partnership with GRAVL and Aria Diagnostics (ARIA), has secured a $5 million Department of Defense (DoD) contract to deploy ANTIDOTE, a pioneering biosecurity platform capable of real-time global pathogen detection. This project marks a significant advancement in decentralized biosurveillance, enabling swift and coordinated responses to public health threats by linking/creating a distributed genomic network that is scalable, redundant and disaster-proof.
ANTIDOTE utilizes the FDA-developed HIVE bioinformatics platform from Embleema, combined with GRAVL’s proven infrastructure for secure sample intake, logistics, and data provenance collection, and ARIA’s specialized capabilities in complex sample collection, RNA and DNA extraction, and targeted PCR pathogen detection. This integrated system enables real-time re-routing of biological samples across a global network of participating NGS and PCR laboratories, ensuring uninterrupted analysis even if one facility experiences disruption—similar to reallocating computing resources dynamically in cloud environments.
“This DoD-funded project is validation that decentralized pathogen surveillance is no longer experimental—it’s now deployable at scale,” says Robert Chu, CEO of Embleema. “Using our secure FDA-developed analytics, GRAVL’s scalable metadata infrastructure, and ARIA’s highly specialized sampling and extraction workflows, we can deliver critical results faster and from anywhere on the globe, significantly boosting biosecurity preparedness.”
GRAVL CEO Gabor Bethlendy adds, “This DoD-funded deployment proves our infrastructure works — even under biosecurity-critical conditions. We’re now bringing that same platform to genome centers and core facilities — enabling researchers to search, order, and submit samples for scientific services in just a few clicks. This isn’t a LIMS — it’s the storefront and fulfillment layer that lets scientists send samples, not emails.”
Aria Diagnostics President Vipin Adhlakha added, “Our specialized molecular workflows, including high-quality RNA and DNA extraction from complex matrices like wastewater, significantly enhance the speed and reliability of downstream genomic analyses. This ensures the rapid identification of pathogens, underpinning ANTIDOTE’s effectiveness in critical public health scenarios.”
This initiative sets a new benchmark for decentralized genomic infrastructure and positions the ANTIDOTE consortium as a critical asset in protecting public health against emerging global biosecurity threats.
About Embleema Embleema delivers next-generation health-data analytics and blockchain-powered solutions that secure and accelerate clinical research, regulatory submissions, and real-world evidence generation. Visit www.embleema.com to learn more.
About GRAVL GRAVL is the digital backbone powering decentralized genomic labs and research facilities. Its platform streamlines online ordering, quoting, sample submission, data delivery, and structured metadata collection, enabling labs to scale scientific operations, improve turnaround times, and simplify complex workflows. Learn more at www.gravl.io.
About Aria Diagnostics, ARIA specializes in advanced molecular diagnostic technologies, providing high-throughput PCR testing and scalable diagnostic solutions for clinical, public health, and government laboratories. More information at www.ariadxs.com.
Media Contacts:
Embleema
Media contact: Robert Chu
E: [email protected]
P: 914-572-8108
https://www.embleema.com/
https://www.linkedin.com/company/embleema/
Gravl Inc.
Media contact: Gabor Bethlendy, Founder
E: [email protected]
P: 617-275-1594
www.gravl.io
https://www.linkedin.com/company/gravl
Aria Diagnostics
Media contact: Vipin Adhlakha, President
E: [email protected]
P: 301-233-0655
www.ariadxs.com
https://www.linkedin.com/company/aria-diagnostics-llc/
View original content:SOURCE Gravl, Inc.
